CINECA IRIS Institutional Research Information System

VIOLA, DAVID
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.173
EU - Europa 4.027
AS - Asia 3.753
SA - Sud America 544
AF - Africa 249
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.759
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.983
DE - Germania 1.332
SG - Singapore 1.175
CN - Cina 1.040
IT - Italia 747
HK - Hong Kong 606
SE - Svezia 565
BR - Brasile 427
GB - Regno Unito 389
VN - Vietnam 312
BG - Bulgaria 235
AT - Austria 158
FR - Francia 147
RU - Federazione Russa 146
CA - Canada 132
TR - Turchia 132
CI - Costa d'Avorio 120
IN - India 120
FI - Finlandia 102
JP - Giappone 101
BD - Bangladesh 57
SN - Senegal 57
AR - Argentina 40
NL - Olanda 36
KR - Corea 32
UA - Ucraina 27
IQ - Iraq 26
MX - Messico 26
PL - Polonia 26
ZA - Sudafrica 23
EC - Ecuador 19
SA - Arabia Saudita 19
MA - Marocco 18
BE - Belgio 17
CH - Svizzera 17
PK - Pakistan 17
CO - Colombia 16
ES - Italia 16
ID - Indonesia 15
UZ - Uzbekistan 13
PH - Filippine 12
VE - Venezuela 12
IR - Iran 11
LT - Lituania 11
UY - Uruguay 10
IE - Irlanda 9
TN - Tunisia 9
AU - Australia 8
JO - Giordania 8
GR - Grecia 7
MY - Malesia 7
AZ - Azerbaigian 6
CL - Cile 6
EG - Egitto 6
HU - Ungheria 6
PY - Paraguay 6
JM - Giamaica 5
LB - Libano 5
PT - Portogallo 5
SK - Slovacchia (Repubblica Slovacca) 5
TW - Taiwan 5
BO - Bolivia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
IL - Israele 4
NG - Nigeria 4
NP - Nepal 4
OM - Oman 4
PA - Panama 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BY - Bielorussia 3
EE - Estonia 3
GA - Gabon 3
HN - Honduras 3
KE - Kenya 3
KZ - Kazakistan 3
LK - Sri Lanka 3
PE - Perù 3
RO - Romania 3
AO - Angola 2
BH - Bahrain 2
BZ - Belize 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EU - Europa 2
KG - Kirghizistan 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
A1 - Anonimo 1
BS - Bahamas 1
DM - Dominica 1
ET - Etiopia 1
GT - Guatemala 1
HR - Croazia 1
Totale 15.748
Salva come PNG Salva come JPEG
Città #
Ashburn 839
Singapore 618
Hong Kong 592
Woodbridge 508
Chandler 506
Fairfield 447
Dallas 440
San Jose 415
Santa Clara 408
Houston 351
Ann Arbor 267
Shanghai 237
Sofia 235
Beijing 225
Seattle 220
Milan 214
Wilmington 206
New York 198
Cambridge 161
Vienna 139
Princeton 131
Los Angeles 129
London 123
Abidjan 120
Boardman 109
Lawrence 95
Lauterbourg 90
Munich 88
Tokyo 86
Ho Chi Minh City 82
Ottawa 82
Medford 75
Florence 62
Serra 60
Boulder 58
Des Moines 58
Dakar 57
Frankfurt am Main 52
Izmir 48
Dearborn 46
Istanbul 46
Nanjing 44
Hanoi 43
Redondo Beach 43
Bremen 40
Hefei 40
Rome 40
Pisa 39
Dong Ket 36
São Paulo 36
Buffalo 34
San Diego 34
Council Bluffs 33
Helsinki 27
Nürnberg 26
Seoul 25
Orem 23
Columbus 22
Fuzhou 22
Turku 22
Düsseldorf 20
Belo Horizonte 19
Amsterdam 18
Jacksonville 17
Redwood City 17
Brussels 16
Changsha 16
Montreal 16
Quanzhou 16
Guangzhou 15
Lancaster 15
Phoenix 15
Redmond 15
Rio de Janeiro 15
Zhengzhou 15
Atlanta 14
Denver 14
Dhaka 14
Ogden 14
San Francisco 14
Washington 14
Jiaxing 13
Toronto 13
Ankara 12
Chicago 12
Nanchang 12
Johannesburg 11
Kunming 11
Norwalk 11
Tashkent 11
Tianjin 11
Warsaw 11
Baghdad 10
Brasília 10
Chengdu 10
Riyadh 10
Shenyang 10
Stockholm 10
The Dalles 10
Wuhan 10
Totale 10.089
Salva come PNG Salva come JPEG
Nome #
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 318
null 259
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 253
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 243
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 234
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 233
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 233
Targeted Therapy in Thyroid Cancer: State of the Art 224
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study 220
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 216
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 215
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 206
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 204
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 203
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 202
Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. 201
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 196
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 195
Il carcinoma tiroideo: nuove prospettive terapeutiche. 191
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 191
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 189
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 188
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 184
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 183
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 179
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 177
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 176
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 175
Role of YAP-1 in Thyroid Tumor Progression and Outcome 174
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 171
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 170
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 170
Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management 168
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 167
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer 166
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 166
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 164
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 164
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 163
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 163
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 162
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 161
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 161
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 161
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 156
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience 154
Infertility in a patient with papillary thyroid carcinoma treated with high doses of 131-I. 151
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 150
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 149
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 149
null 146
Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer 145
BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer 144
An idic(15) associated with POF (premature ovarian failure): Molecular cytogenetic definition of a case and review of the literature. 143
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 143
Medullary thyroid carcinoma in children 141
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 138
Cabozantinib: An orphan drug for thyroid cancer 136
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 136
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 134
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 133
BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma 132
Management of Medullary Thyroid Cancer 130
Protocolli gestionali-diagnostico-terapeutico-assistenziali in chirurgica tiroidea. 2° Consensus Conference. 129
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 129
Proteinuria is a late-onset adverse event in patients treated with cabozantinib 128
La tiroide come sede di metastasi 127
The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer 126
Short term follow-up outcome of stage I thyroid cancer patients is worst when BRAFV600E mutation is present in the primary tumor. 125
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment 125
BRAFV600E mutation is an indipendent bad prognostic factor for the out come of patients with papillary thyroid carcinoma: a 15-year median follow-up study. 124
The Integrity of Tumor Capsule Identifies a Subgroup of Indolent Cases Not Only Among the Follicular (FVPTC) But Also in Classic Variant of Papillary Thyroid Cancer (CVPTC) 124
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 120
. Utilità della ricerca della mutazione di BRAF nel tumore primitivo di pazienti affetti da carcinoma papillare della tiroide a basso rischio. 117
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 117
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 116
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer 113
Targeted therapies for thyroid cancer. 112
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 112
null 110
null 107
null 105
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. 101
Biological and molecular markers for diagnosis, follow-up and prognosis of patients affected by thyroid cancer. 98
KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) 96
null 86
null 86
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study. 85
null 84
Ret Oncogene and Thyroid Carcinoma 81
null 79
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer 79
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. 79
BRAF(V600E) mutations are correlated with a lower expression of both NIS and TPO mRNA expression in papillary thyroid cancer (PTC) 77
Long Term Outcomes of Patients Undergoing Ablation With Low Activities of RAI. 73
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) 71
How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level. 71
Totale 15.319
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.946
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.946
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021128 0 0 0 0 0 0 0 0 0 0 0 128
2021/20221.101 26 39 22 62 229 159 33 46 59 46 77 303
2022/20231.835 207 310 154 150 163 201 35 138 333 13 118 13
2023/20241.022 116 104 124 69 132 198 64 19 17 18 53 108
2024/20253.298 38 134 40 184 365 294 226 148 387 463 296 723
2025/20263.701 325 504 417 341 418 296 516 155 230 344 149 6
Totale 15.979